{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:32:40Z","timestamp":1787761960319,"version":"build-2784847793"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives:<\/jats:title>\n                    <jats:p>Allogeneic stem cell transplantation (Allo-SCT) in elderly patients is a growing practice. We aimed to determine the graft-versus-host disease (GVHD) relapse-free survival (GRFS) in patients \u226565 years who underwent Allo-SCT in two countries from Latin America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods:<\/jats:title>\n                    <jats:p>We performed a retrospective analysis of patients \u226565 years who underwent Allo-SCT in Argentina and Brazil from 2007 to 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ninety-eight patients were evaluated, with primary diagnoses of acute myeloid leukemia and myelodysplastic syndrome; 30% of patients had a hematopoietic cell transplant-comorbidity index (HCT-CI) score \u22653 and 49% were in complete remission. Donor types included matched sibling (n = 41), matched unrelated (n = 31), and haploidentical (HID; n = 26) donors. The conditioning regimen was myeloablative in 28 patients (14 busulfan pharmacokinetically [PK]-guided) and reduced-intensity in 70 patients.<\/jats:p>\n                    <jats:p>The two-year non-relapse mortality (NRM) was 29%, with a higher NRM in melphalan-based compared to other conditionings (51% vs. 33%, p = 0.02). The two-year relapse rate was 24%, with a reduction in PK-guided busulfan (0% vs. 28%, p = 0.03). The two-year overall survival (OS) and GRFS was 52% and 38%, respectively, with a significant reduction in GRFS in HCT-CI \u22653 (27% vs. others 42%, p = 0.02) and donors \u226540 years (29% vs. &lt;40 years 55%, p = 0.02). These variables remained significantly associated with GRFS after multivariate analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this cohort of elderly patients from Argentina and Brazil undergoing Allo-SCT, donor age and comorbidities significantly influenced GRFS. The role of the conditioning regimen in this population deserves further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.56875\/2589-0646.1042","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T11:30:11Z","timestamp":1686655811000},"page":"330-336","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Donor Age Influences Graft-Versus-Host Disease Relapse-Free Survival after Allogeneic Stem Cell Transplant in Elderly Patients in Two Countries from Latin America"],"prefix":"10.4103","volume":"16","author":[{"given":"Mariano","family":"Berro","sequence":"first","affiliation":[{"name":"HSCT Unit, Hospital Universitario Austral, Pilar, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Israelita Albert Einstein, San Pablo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Milovic","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Aleman, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Castro","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Privado de Cordoba, Cordoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres P.","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Privado de Cordoba, Cordoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Ferini","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Real","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Aleman, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Vitriu","sequence":"additional","affiliation":[{"name":"HSCT Unit, Instituto Alexander Fleming, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto G.","family":"Conca","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Bendek","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Yantorno","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Italiano La Plata, La Plata, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana M.","family":"Rol\u00f3n","sequence":"additional","affiliation":[{"name":"HSCT Unit, FUNDALEU, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Saslavsky","sequence":"additional","affiliation":[{"name":"HSCT Unit, CETRAMOR, Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Jarchum","sequence":"additional","affiliation":[{"name":"HSCT Unit, Sanatorio Allende, Cordoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Cerutti","sequence":"additional","affiliation":[{"name":"HSCT Unit, Sanatorio Britanico, Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya C.","family":"da Silva","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Israelita Albert Einstein, San Pablo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgani","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Israelita Albert Einstein, San Pablo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Riera","sequence":"additional","affiliation":[{"name":"HSCT Unit, CEMIC, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Arbelbide","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Kusminsky","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Universitario Austral, Pilar, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Basquiera","sequence":"additional","affiliation":[{"name":"HSCT Unit, Hospital Privado de Cordoba, Cordoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of GATMO-TC: Grupo Argentino de Trasplante de Medula Osea y Terapia Celular","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"issue":"5","key":"R2-20241211","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"issue":"9","key":"R3-20241211","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid diagnosis","volume":"35","author":"Bullinger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"R4-20241211","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12885-019-6472-9","article-title":"Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers","volume":"20","author":"Fowler","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"R5-20241211","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2012.067892","article-title":"Parameters detected by geriatric and quality of life assessment in older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome","volume":"98","author":"Deschler","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"R6-20241211","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.bbmt.2017.05.035","article-title":"Current use and trends in hematopoietic cell transplantation in the United States","volume":"23","author":"D Souza","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"R7-20241211","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1007\/s00277-019-03771-2","article-title":"Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"98","author":"Giebel","year":"2019","journal-title":"Ann Hematol"},{"issue":"11","key":"R8-20241211","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","article-title":"Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG- ACRIN and CIBMTR study","volume":"33","author":"Ustun","year":"2019","journal-title":"Leukemia"},{"issue":"24","key":"R9-20241211","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.1182\/blood-2011-12-380162","article-title":"Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome","volume":"119","author":"Kroger","year":"2012","journal-title":"Blood"},{"issue":"9","key":"R10-20241211","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ajh.24102","article-title":"Myelodysplastic syndrome: 2015 update on diagnosis risk-stratification and management","volume":"90","author":"Garcia Manero","year":"2015","journal-title":"Am J Hematol"},{"issue":"9","key":"R11-20241211","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.bbmt.2012.05.003","article-title":"Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine","volume":"18","author":"Platzbecker","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"29","key":"R12-20241211","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biological age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"R13-20241211","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"4","key":"R14-20241211","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamaoncol.2019.5140","article-title":"Comparison of patient age groups in transplantation for myelodysplastic syndrome","volume":"6","author":"Atallah","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10","key":"R15-20241211","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bbmt.2019.05.037","article-title":"Outcome for allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the acute leukemia working party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"Ringden","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"R16-20241211","first-page":"201","article-title":"Allogeneic hematopoietic stem cell transplantation in the elderly. Predicting the risk for non relapse mortality","volume":"75","author":"Berro","year":"2015","journal-title":"Medicina"},{"issue":"1","key":"R17-20241211","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jgo.2019.05.022","article-title":"The use of comprehensive geriatric assessment in older patients before allogeneic hematopoietic stem cell transplantation: a cross-sectional study","volume":"11","author":"Rodrigues","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"R18-20241211","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bbmt.2018.01.002","article-title":"Blood and marrow transplant clinical trials network report on the development of novel endpoints and selection of promising approaches for graft-versus-host disease prevention trials","volume":"24","author":"Pasquini","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"R19-20241211","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/bmt.2015.180","article-title":"In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?","volume":"50","author":"Peffault de Latour","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"R20-20241211","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbmt.2019.12.766","article-title":"Outcomes of allogeneic stem cell transplant for elderly patients with hematologic malignancies","volume":"26","author":"Hsu","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"R21-20241211","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.bbmt.2012.06.001","article-title":"Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial","volume":"18","author":"Finke","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"R22-20241211","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based conditioning: considerations from the American society for blood and marrow transplantation practice guidelines committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"R23-20241211","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"R24-20241211","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41409-018-0405-0","article-title":"Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML\/MDS","volume":"54","author":"Alatrash","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"R25-20241211","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood.2019003662","article-title":"Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?","volume":"135","author":"Ciurea","year":"2020","journal-title":"Blood"},{"issue":"5","key":"R26-20241211","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2018.02.006","article-title":"Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most","volume":"24","author":"Shaw","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"R27-20241211","doi-asserted-by":"crossref","first-page":"662.e1","DOI":"10.1016\/j.jtct.2021.04.014","article-title":"Engrafted donor-derived clonal hematopoiesis after allogeneic hematopoietic cell transplantation is associated with chronic graft-versus-host disease requiring immunosuppressive therapy, but no adverse impact on transplant survival or relapse","volume":"27","author":"Newell","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"R28-20241211","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/bmt.2013.14","article-title":"Donor choice according to age for allo-SCT for AML in complete remission","volume":"48","author":"Ayuk","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"R29-20241211","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bbmt.2020.05.010","article-title":"Pretransplantation cognitive dysfunction in advanced-age hematologic cancers: predictors and associated outcomes","volume":"26","author":"Root","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"R30-20241211","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.bbmt.2019.07.030","article-title":"Hematopoietic cell transplant\/related toxicities and mortality in frail recipients","volume":"25","author":"Pamukcuoglu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"R31-20241211","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbmt.2019.08.022","article-title":"Functional status as measures by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplantation recipients","volume":"26","author":"Huang L-W, Sheng","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"R32-20241211","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/bloodadvances.2020001719","article-title":"Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes","volume":"4","author":"Olin","year":"2020","journal-title":"Blood Adv"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:12:50Z","timestamp":1787760770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.56875\/2589-0646.1042","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"2021-09-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}